Key Takeaways
- Novo Nordisk received an FDA warning letter on March 5 concerning unreported adverse events associated with semaglutide, found in Ozempic and Wegovy.
- The letter referenced three fatalities, including a suicide that the company allegedly failed to investigate or report on time.
- The pharmaceutical giant has a 14-day deadline to outline its corrective measures to the FDA.
- Novo maintains that this warning will not affect manufacturing operations or its financial projections.
- Shares of NVO have declined 27% year to date, currently hovering near $38.32.
Novo Nordisk is facing mounting challenges in 2026, and the latest FDA action adds to its troubles.
The U.S. Food and Drug Administration dispatched a warning letter to the Copenhagen-based pharmaceutical company dated March 5, highlighting “serious violations” in its adverse event reporting procedures for semaglutide, the active compound in its blockbuster drugs Ozempic and Wegovy.
These compliance issues came to light during a regulatory inspection conducted at one of Novo’s New Jersey facilities in 2025.
The warning letter specifically mentioned three fatalities—two deaths plus one suicide case—where the FDA determined that Novo didn’t properly investigate or submit reports for the suicide within mandatory timeframes.
Importantly, the FDA clarified that it is not establishing a causal relationship between the medications and these deaths. The agency’s concern centers on procedural compliance rather than direct attribution.
“FDA relies on the complete, accurate, and timely submission of ADEs to monitor a product’s safety profile,” the regulatory body stated, using the abbreviation for adverse drug events.
Novo Nordisk must inform the FDA within two weeks about its planned corrective actions to address these compliance gaps.
In a public statement, the pharmaceutical company indicated it has been working “diligently” to resolve the FDA’s concerns. It confirmed submitting an initial response along with seven subsequent updates to the agency.
The company stated that the cases in question “have been evaluated” and are now “processed and reported appropriately.” Notably, Novo did not dispute the initial reporting failures.
Mounting Regulatory Scrutiny
This warning represents just one piece of a broader regulatory puzzle for Novo. In December, the company received another FDA warning letter targeting its Bloomington, Indiana manufacturing site for Good Manufacturing Practice violations.
Additionally, the FDA sent two separate letters in February criticizing promotional materials for Ozempic and Wegovy for containing “false or misleading claims” regarding effectiveness and risks. A February 26 correspondence specifically challenged Novo for suggesting Ozempic’s superiority over competitor medications.
In its official response, Novo acknowledged the regulatory landscape, stating: “We work in a highly regulated space.”
Despite these setbacks, the company maintains that the most recent warning letter will not disrupt its manufacturing capabilities or alter the financial outlook previously communicated to shareholders.
Shares Tumble 27% in 2026
NVO stock has experienced significant downward pressure throughout 2026. Trading at approximately $38.32, the stock has shed 27% of its value year to date, representing a substantial retreat from previous peaks.
Multiple headwinds have contributed to the decline—intensifying regulatory oversight combined with fierce competition from Eli Lilly’s competing GLP-1 medication Mounjaro have dampened investor confidence.
Political factors have compounded the challenges. Health Secretary RFK Jr. has openly criticized Ozempic’s pricing structure, and previously blocked a Biden administration initiative that would have extended Medicare coverage of GLP-1 medications to approximately 7 million beneficiaries.
As of Tuesday afternoon, the stock remained at $38.32 per share.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
